Haleon plc (NYSE:HLN) Shares Acquired by Bain Capital Public Equity Management II LLC

Bain Capital Public Equity Management II LLC boosted its position in Haleon plc (NYSE:HLN - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,844,010 shares of the company's stock after buying an additional 165,929 shares during the period. Haleon makes up approximately 1.2% of Bain Capital Public Equity Management II LLC's investment portfolio, making the stock its 20th largest holding. Bain Capital Public Equity Management II LLC owned 0.06% of Haleon worth $27,132,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Sierra Ocean LLC purchased a new stake in shares of Haleon in the 4th quarter valued at $26,000. Versant Capital Management Inc grew its position in Haleon by 2,029.1% during the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock worth $34,000 after purchasing an additional 3,348 shares during the period. Geneos Wealth Management Inc. purchased a new position in shares of Haleon during the 4th quarter valued at about $35,000. Spire Wealth Management acquired a new position in shares of Haleon in the 4th quarter valued at about $39,000. Finally, FIL Ltd boosted its stake in shares of Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock worth $39,000 after buying an additional 1,270 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on HLN shares. HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Barclays reiterated an "overweight" rating on shares of Haleon in a research note on Tuesday. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Finally, Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a research note on Friday. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Haleon currently has an average rating of "Moderate Buy" and a consensus target price of $11.25.

Haleon Price Performance

Shares of HLN stock traded up $0.20 on Friday, reaching $10.77. 15,262,457 shares of the company were exchanged, compared to its average volume of 7,719,730. The company has a market cap of $48.59 billion, a price-to-earnings ratio of 31.68, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a 1 year low of $8.22 and a 1 year high of $10.85. The business has a 50-day moving average price of $10.20 and a 200 day moving average price of $9.83. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. The business had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Equities research analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. This is a boost from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is 58.97%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.